Introduction
In 2016, a randomized controlled trial reported that a course of late preterm betamethasone (34 þ0 -36 þ6 weeks) given to women with singleton pregnancies considered at risk for delivery <37 weeks was associated with a significant decrease in the risk of newborn respiratory complications. 1 These results prompted statements from the American College of Obstetricians and Gynecologists (ACOG) and the Society for MaternalFetal Medicine (SMFM) in April 2016 and 2 subsequent guidance documents published later in 2016 supporting antenatal steroids for selected women with late preterm (34 þ0 -36 þ6 weeks) singleton pregnancies considered to be at risk for preterm delivery. 2, 3 Excluded from these recommendations were multiple pregnancies, those with chorioamnionitis, and those with prepregnancy diabetes.
Nationally, approximately 70% of preterm births and 8% of all deliveries occur at 34-36 weeks. 4 Therefore, the new guidance statements have the potential to expose a much larger percentage of the pregnant population to antenatal steroids. For antenatal steroid exposure at <34 weeks of gestation, there are clear benefits for those born prematurely and no obvious adverse effects on long-term follow-up after a single course of antenatal steroids. 5 However, in the last 2 years a number of researchers raised concerns about the potential for negative as well as positive effects of antenatal steroids in general [6] [7] [8] [9] and specifically about the risk-benefit ratio for late preterm steroids. [10] [11] [12] In particular there is a paucity of data on long-term outcomes following antenatal steroid exposure at 34 weeks. 12 Given the large number of pregnancies potentially affected by this change in practice, the short-and longterm risk-benefit ratio is an important consideration. Our goal was to review antenatal steroid use prior to the 2016 ACOG and SMFM statements and to assess the potential impact of implementing the 2016 recommendations.
Materials and Methods
This retrospective cohort study used chartabstracted data from deliveries at 12 centers participating in the Obstetrics Clinical Outcomes Assessment Program (OB COAP), a quality initiative in Washington State. These centers all had level II or III neonatal units and included both urban and rural settings. Centers contributing data for all or part of the study period (Jan. 1, 2012, through March 31, 2016) were included in the study. The analysis was restricted to singleton pregnancies delivering between 23 þ0 and 42 þ6 weeks of gestation. Deliveries with missing gestational age at delivery, fetal anomalies, or antepartum demise were excluded.
OB COAP captures consecutive deliveries at participating centers and records a wide range of variables including those related to maternal demographic characteristics, prepregnancy health, pregnancy complications, labor course, delivery, and postnatal outcomes for mothers and newborns. Abstracted data are entered into a cloud-based, standardized data tool. Data undergo realtime quality checks performed both at the site and aggregate level. Monthly web meetings and unlimited access to OB COAP staff for education and support are available. Audit of OB COAP data against billing records with a minimum of 90% agreement is required for the program.
The Western Institutional Review Board determined in 2015 that OB COAP is not engaged in human subjects research and therefore is exempt from institutional review board review.
Early preterm birth was defined as delivery between 23 þ0 and 33 þ6 weeks and late preterm birth as delivery between 34 þ0 and 36 þ6 weeks of gestation. Pregnancies that delivered in the late preterm period were divided into 2 groups based on the 2016 ACOG/SMFM guidance: those that would be considered potentially eligible and those that would be considered ineligible for late preterm antenatal steroids. Those considered to be ineligible for antenatal steroids were further divided into those that would be considered ineligible due to having already received antenatal steroids and those that had not received earlier steroids but were ineligible due to chorioamnionitis or prepregnancy diabetes. Data on maternal antibiotic treatment for chorioamnionitis were available only for 2015 and 2016.
Newborn outcomes evaluated included respiratory complications, need for resuscitation at delivery, glucose instability, and admission to the neonatal intensive care unit (NICU). Other descriptive variables included maternal demographics and pregnancy, delivery, and newborn characteristics.
Descriptive statistics included the rate of preterm delivery and late preterm delivery, the percentage of all deliveries that received antenatal steroids, and the percentage that received antenatal steroids and subsequently delivered late preterm or at term. We also report the percentage of early preterm deliveries where the opportunity for antenatal steroids was missed (those delivering <34 weeks of gestation that did not receive antenatal steroids).
Maternal demographic, pregnancy, delivery, and newborn characteristics are reported for late preterm deliveries by potential eligibility for antenatal steroids. Newborn outcomes among late preterm deliveries are reported by potential eligibility for antenatal steroids (eligible vs ineligible) and gestational week at delivery (34, 35, 36 weeks). Frequency of outcomes between late preterm deliveries potentially eligible or ineligible for antenatal steroids was compared using c 2 tests. As deliveries ineligible for antenatal steroids represented a heterogeneous group in terms of obstetric risk factors, we also qualitatively compared newborn outcomes between potential eligibility and ineligibility for the late preterm antenatal steroids, subdividing the ineligible group into those who were ineligible due to prior steroids and those who were ineligible due to chorioamnionitis or prepregnancy diabetes.
Results
A total of 62,300 singleton deliveries from 12 centers were entered into the database during the study period. Of these, 60,190 deliveries (97%) met the inclusion criteria. The prevalence of preterm delivery (23 þ0 -36 þ6 weeks) was 6.6% (n ¼ 3976). Of preterm deliveries, 74% were in the late preterm period (n ¼ 2942), representing 4.9% of all singleton deliveries.
A total of 3% (n ¼ 1908) of all pregnancies received antenatal steroids at some point. Of the 1908 pregnancies exposed to antenatal steroids, 42.3% (n ¼ 808) delivered in the early preterm period, 25.5% (n ¼ 486) in the late preterm period, and 32.2% (n ¼ 614) at term. Among the 1034 early preterm deliveries the opportunity for antenatal steroids was missed in 21.9% (n ¼ 226).
Based on the 2016 guidance, 80.3% (n ¼ 2363) of late preterm deliveries would be considered eligible for antenatal steroids if late preterm birth was anticipated with enough time to administer steroids. Of the late preterm population, 16.3% (480/2942) were ineligible due to having already received antenatal steroids and 3.4% (99/2942) were ineligible due to prepregnancy diabetes or chorioamnionitis, Those potentially eligible for antenatal steroids tended to be younger, were less likely to be African American non-Hispanic, had a lower prevalence of prepregnancy hypertension, and had a lower prevalence of preeclampsia/gestational hypertension, compared with those who were ineligible (Table 1) . Additionally, compared with those who were ineligible, those potentially eligible for antenatal steroids were more likely to have a vaginal delivery and to deliver at 36 weeks of gestation.
Newborn respiratory complications were recorded in 10.6% (312/2942) of all late preterm deliveries in the study population and 79.5% (248/312) of these occurred in pregnancies potentially eligible for antenatal steroids. Examining gestational week at delivery among newborns with respiratory complications by eligibility for antenatal steroids revealed that more than two thirds (69.0%; 171/248) of newborn respiratory complications in those potentially eligible for antenatal steroids occurred among those delivering at 34-35 weeks ( Figure) .
Of pregnancies delivering at 34 and 35 weeks of gestation, those potentially eligible for antenatal steroids had a higher rate of newborn respiratory complications than those who were ineligible (P < .05) ( ajog.org
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antenatal steroids, those who were potentially eligible had a lower rate of NICU admission regardless of gestational week at delivery (Table 2) . Subdividing those ineligible for steroids by reason for ineligibility (prior receipt of steroids, prepregnancy diabetes, or chorioamnionitis) and comparing them to those who were potentially eligible, slightly different patterns emerged. At nearly all gestational weeks, those ineligible for antenatal steroids due to prepregnancy diabetes or chorioamnionitis had the highest prevalence of all included outcomes (Table 3) . Among newborns delivering at 34 and 35 weeks, compared with those who were ineligible due to prior receipt of antenatal steroids, those who were potentially eligible had a higher prevalence of respiratory complications. However, this difference was not apparent among those delivering at 36 weeks. A similar pattern was observed for resuscitation at delivery. Consistent patterns were less clear for glucose instability and NICU admission.
Comment
Our study showed that antenatal steroid use for early preterm delivery is still suboptimal. In examining late preterm deliveries we found that those potentially ineligible based on prepregnancy diabetes or chorioamnionitis were at the highest risk for respiratory complications regardless of gestational week at delivery. Further, while the majority of late preterm deliveries among those potentially eligible for antenatal steroids occurred at 36 weeks, the majority of respiratory complications in the steroideligible group occurred among those delivering at 34-35 weeks of gestation.
The Antenatal Late Preterm Steroids (ALPS) trial demonstrated statistically significant benefits of antenatal steroids for late preterm delivery, but there remain a number of issues surrounding implementation of the findings, which our study illustrates. 1 First is how accurately preterm delivery can be predicted in the general population to minimize steroid exposure for those who ultimately deliver at term. 13 Our findings highlight how difficult this is to achieve for early preterm deliveries as nearly 60% of singleton pregnancies receiving antenatal steroids in our study population delivered at 34 weeks, and one third delivered at term. Conversely the opportunity for appropriate use of steroids was missed in approximately 1 in 5 early preterm deliveries. Similarly in the ALPS trial only 11% of pregnancies screened for the trial were eligible and even then 16% delivered at term. 1 Of the potentially late preterm steroid-eligible group, we do not know how many will receive steroids prior to preterm delivery nor how many more pregnancies may be exposed to late preterm steroids and ultimately deliver at 37 weeks. In addition to those that ultimately deliver at term, there is the possibility of "treatment creep" to include other groups such as multiple pregnancies, prepregnancy diabetics, and scheduled cesarean deliveries <39 weeks of gestation. 14 This could further increase steroid exposure to the pregnant population. Without adherence to strict criteria for determining risk for preterm delivery, extending antenatal steroid use to the late preterm population could lead to a substantially larger population of newborns being unnecessarily exposed to antenatal steroids.
The second issue relates to which pregnancies are most likely to benefit from late preterm steroids. In our study, the highest rate of newborn complications in late preterm deliveries was in the group that had prepregnancy diabetes or chorioamnionitis and had not received earlier steroids. While urgent delivery for overt chorioamnionitis likely precludes receipt of late preterm steroids, the situation with prepregnancy diabetes is more complicated. Prepregnancy diabetes is not considered an absolute contraindication to antenatal steroids but the use of antenatal steroids can pose a challenge for glucose control and may increase risks for exacerbation of neonatal hypoglycemia. 15 However, antenatal steroids, if effective, may significantly improve newborn respiratory outcomes in this high-risk group.
The third issue relates to the upper limit for eligibility for antenatal steroids. Fetal respiratory maturation continues throughout the late prenatal period. More than half of the potentially steroideligible late preterm deliveries in our study were at 36 weeks, when the The last issue relates to the unknown risks of late preterm steroid exposure, particularly long-term neurodevelopment. There are very limited data relating to long-term follow-up after exposure to antenatal steroids >34 weeks of gestation and there is a growing body of literature highlighting the effects of antenatal steroids, some of which have the potential for harm. 7 Dalziel et al 17 followed up 192 adults (87 exposed to betamethasone in utero and 105 exposed to placebo) from a randomized controlled trial and reported no obvious adverse health or neurodevelopmental outcomes following preterm antenatal steroids. However, 2 other long-term follow-up studies of children raised the possibility of adverse neurodevelopmental effects associated with exposure to antenatal steroids later in pregnancy. 18, 19 An additional potential for harm relates to the 60% increase in neonatal hypoglycemia reported in the ALPS trial. While this may appear to be a fairly minor short-term trade-off for improved respiratory outcomes, it is unclear if this side effect is benign in the long-term. Two recent studies produced conflicting results: one reporting transient mild neonatal hypoglycemia to be associated with no increase in adverse neurodevelopmental outcomes at 2 years of age and another reporting lower achievement test scores at 10 years. 20, 21 The majority of those eligible for late preterm antenatal steroids delivered at 36 weeks of gestation, when their risk of glucose instability was lowest. This raises questions regarding the increased risk of hypoglycemia and the added burden on the health care system as well as potential long-term outcomes.
Strengths of our study include the large study population, the depth of clinical information, and the ability to evaluate outcomes in the late preterm delivery population prior to the SMFM and ACOG statements. Limitations of our study include that data on chorioamnionitis were not available throughout the entire study period. Additionally, the study did not explore whether late preterm deliveries were identified as at risk for preterm birth prenatally nor whether there would have been adequate time to administer steroids before birth. We thereby likely overestimated the potentially antenatal steroid-eligible group. Conversely, we likely underestimated the number of pregnancies potentially eligible for late preterm antenatal steroids since it is probable that a portion of term deliveries were considered at high risk for late preterm delivery. The timing of earlier antenatal steroids was also not known nor was the number of earlier courses. Therefore, some women may have received multiple doses or additional doses >34 weeks, although anecdotally adherence to a 34-week cutoff was the typical practice in our area prior to 2016. Mode of delivery is also a risk factor for respiratory complications. However, in our study, stratification by mode of delivery (planned cesarean, cesarean in labor, and vaginal birth) in addition to gestational week at delivery resulted in such small numbers in some cells, that meaningful assessment of the influence of mode of delivery was precluded. Our study also had less strictly defined outcome measures compared to the ALPS trial, so "glucose instability" was based on clinical documentation of this issue rather than specific blood glucose levels and "respiratory complications" were not subdivided into specific diagnoses. ajog.org
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Finally, we did not evaluate the proportion of singleton pregnancies with prelabor ruptured membranes in the late preterm period for which use of late preterm antenatal steroids remains controversial. While the 2016 SMFM and ACOG statements about late preterm antenatal steroids did not specifically address such use in the setting of prelabor rupture of the membranes, this group made up 20% of the population in the ALPS trial on which these statements were based.
In recognition of the benefits of late preterm antenatal steroids professional organizations issued statements supporting the use of late preterm steroids in a select group of pregnant women considered at high risk of delivery <37 weeks of gestation. However, the implementation raises questions including how to accurately predict late preterm birth, who should receive late preterm antenatal steroids based on pregnancy complications and gestational age, what the economic and health implications may be, and the effect of antenatal steroids (either directly or indirectly through hypoglycemia) on long-term outcomes.
Given the difficulty in accurately predicting preterm delivery and the lack of information about the long-term neurodevelopmental outcomes associated with late preterm steroids, this intervention should be targeted to those most likely to gain benefit. One of the limitations of the ALPS trial is that it evaluated outcomes for those who received steroids throughout the late preterm period. However, the rate of respiratory complications is substantially lower at 36 compared to 34 weeks of gestation. Consequently the estimated number needed to treat will change across the late preterm period and is likely considerably higher at 36 weeks than it is at 34 weeks. In addition, although the ALPS trial was not statistically powered to evaluate the effect of betamethasone by gestational week, a subgroup analysis of those recruited at 36 weeks reported little to no difference in the rate of the primary outcome or of severe respiratory outcomes in the placebo and betamethasone groups (primary outcome: placebo 7.1% vs control 7.1%; severe respiratory outcome: placebo 3.8% vs control 2.9%). Our findings suggest that restricting antenatal steroids to eligible pregnancies at 34-35 weeks may capture most of the respiratory complications among late preterm deliveries while minimizing antenatal steroid exposure at the population level. Careful consideration is needed to ensure that guidelines target those pregnancies that could benefit most from late preterm steroids while minimizing unnecessary exposure. Future monitoring of the effect of late preterm antenatal steroids is essential to evaluate short-and long-term outcomes of this change in practice.
n
